News summary produced by Claude AI
Health authorities are implementing a targeted vaccination initiative focused on reaching approximately one million teenagers and young adults amid rising concerns over meningitis B cases. The programme is designed to provide protection to those identified as facing the greatest risk during the current period.
Meningitis is an infection affecting the protective membranes surrounding the brain and spinal cord. While the condition can impact individuals of any age, it occurs most frequently in babies, young children, teenagers, and young adults. The disease can become serious rapidly if left untreated. Infections may be caused by either bacteria or viruses, which can be identified through diagnostic testing. Bacterial meningitis, though less common than its viral counterpart, carries greater severity and can lead to blood poisoning, sepsis, and brain complications. Meningitis B, or MenB, accounts for the majority of severe meningococcal disease cases in the UK. Official data indicates 378 cases of invasive meningococcal disease were recorded in 2024-2025.
Symptoms of meningitis can emerge suddenly and include high fever, severe headache, stiff neck, vomiting, diarrhoea, joint and muscle pain, sensitivity to light, cold extremities, seizures, confusion, and extreme sleepiness. A characteristic rash that does not fade under pressure from glass may also appear. Because meningitis can be life-threatening, individuals experiencing these symptoms should seek immediate medical attention at emergency departments or contact emergency services.
Two primary vaccines offer protection against major causes of meningitis. The MenACWY vaccine protects against four bacterial groups and is offered to teenagers at age 14, with free access available until age 25 for those who missed vaccination. The MenB vaccine protects against meningococcal group B and is recommended for babies beginning at eight weeks of age, with additional doses at 12 weeks and one year. Additional vaccines, including those for diphtheria, tetanus, whooping cough, measles, mumps, rubella, and chickenpox, can provide supplementary protection.
The targeted vaccination programme this summer will offer two free doses of the MenB vaccine to Year 13 pupils and individuals under 25 beginning university or residential further education in the autumn. Experts indicate this population faces elevated risk due to shared accommodation and close contact patterns typical of campus environments. Transmission occurs through saliva exchange via coughs, sneezes, kissing, or sharing food and drinks. Early antibiotic treatment of exposed individuals and vaccination are the most effective prevention strategies.